Ewing's sarcoma

11 trials 8 recruiting MedDRA PT
11 Registered trials
8 Recruiting
9 Unique sponsors
12 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 7
V Various (ATC V) 1
L Oncology (ATC L) 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Alkylating agent 2 substances
Topoisomerase I inhibitor 2 substances
Radiopharmaceutical 1 substance
CDK inhibitor 1 substance
Kinase inhibitor 1 substance
Monoclonal antibody 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 3 Phase I/II: 2 Phase I: 3 Phase I (Other): 1

Filter these 11 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 11 trials

Phase III

1 trial
  • The University Of Birmingham Academic
    IMP not specified
    2024-511989-36-00 5 countries 2025 n=498
    Recruiting

Phase II/III

1 trial
  • The University Of Birmingham Academic
    LENVATINIB
    2024-516078-31-00 10 countries 2015 n=436
    Recruiting

Phase II

3 trials
  • Fondazione Santobono Pausilipon Onlus Academic
    TREOSULFAN
    2024-518912-37-01 1 country n=60
    Pending
  • Instytut Matki I Dziecka Academic
    NAXITAMAB
    2024-514441-11-00 1 country 2023 n=24
    Recruiting
  • Universitaetsklinikum Tuebingen AöR Academic
    PERVI-FUS, PERVI-NEO, 11902A
    2024-511337-35-00 1 country 2023 n=23
    Recruiting

Phase I/II

2 trials
  • Pfizer Inc. Commercial
    CYCLOPHOSPHAMIDE MONOHYDRATE; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; PALBOCICLIB; TEMOZOLOMIDE; TOPOTECAN
    2024-511975-14-00 5 countries 2022 n=29
    Ended
  • Centre Oscar Lambret Academic
    IMP not specified
    2024-513470-22-00 1 country 2019 n=63
    Ended

Phase I

3 trials
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • Universitaet Muenster Academic
    GD2IL18CART
    2022-501725-21-00 1 country 2024 n=48
    Recruiting
  • Universitaet Muenster Academic
    GD2IL18CART
    2025-521497-34-00 1 country 2025 n=20
    Recruiting

Phase I (Other)

1 trial
  • ITM Solucin GmbH Commercial
    L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) EDOTREOTIDE
    2024-512831-66-00 3 countries 2025 n=16 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Universitaet Muenster Academic 2 Phase I 2
The University Of Birmingham Academic 2 Phase II/III, Phase III 2
BeOne Medicines AG Commercial 1 Phase I 1
ITM Solucin GmbH Commercial 1 Phase I (Other) 1
Pfizer Inc. Commercial 1 Phase I/II 0
Fondazione Santobono Pausilipon Onlus Academic 1 Phase II 0
Instytut Matki I Dziecka Academic 1 Phase II 1
Universitaetsklinikum Tuebingen AöR Academic 1 Phase II 1
Centre Oscar Lambret Academic 1 Phase I/II 0
New trials by year
2019
1
2022
1
2023
2
2024
2
2025
3
← All indication landscapes